Bladder cancer is among the top ten most common cancers in the UK. In men it is the fourth most common, behind lung, prostate and large bowel cancers. It develops mostly in people between the ages of 60 and 79 and its first visible sign is often blood in the urine. Other symptoms are shared with common bladder infection, such as frequent urination, stinging and pain across the pubic bone.
Superficial bladder cancer - restricted to the lining of the bladder - accounts for 70% of all bladder cancer in the UK. If neglected, it can progress deeper to invade the muscle lining of the bladder and becomes a much more serious threat, potentially spreading to the body's vital organs.
ImmuCyst 81mg is a first line immunotherapy treatment for superficial bladder cancer. It is made from a culture of the Connaught strain of BCG (Bacillus Calmette-Guerin), which is instilled directly into the bladder via a catheter.
ImmuCyst 81mg was launched in 2001 and is the market leading BCG brand in the UK. It works by selectively stimulating an immune response at the tumour site within the bladder wall destroying the cancerous cells.
The product is also backed by Cambridge Laboratories' expertise in the oncology field, plus our strong product support network including a dedicated BCG hotline and ongoing commitment to specialist nurse and consultant training. By working in partnership with our customers we are constantly seeking to maximise the product's performance.